Intranasal beclomethasone in severe rhinosinusitis and nasal polyps.
The study was designed to measure the effect of inhaled beclomethasone on patients with severe symptomatic rhinosinusitis and nasal polyposis following 12 weeks of therapy. Only one of eight patients had improved nasal symptoms and a reduction in the degree of nasal obstruction. Except for an occasional patient intranasal beclomethasone in the recommended dosage is not effective in the management of chronic severe symptomatic rhinosinusitis.
D000281:Administration, Intranasal; D000328:Adult; D000336:Aerosols; D000368:Aged; D001507:Beclomethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008443:Maxillary Sinus / Q000000981:diagnostic imaging; D008875:Middle Aged; D009298:Nasal Polyps / Q000000981:diagnostic imaging / Q000188:drug therapy*; D012852:Sinusitis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
D000336:Aerosols; D001507:Beclomethasone